Luis Carlos Saiz

Dr. Luis Carlos Saiz

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LSLuis Carlos Saiz
Luis Carlos Saiz
JGJavier Gorricho
Javier Gorricho
JGJavier Garjón
Javier Garjón
MCMª Concepción Celaya
Mª Concepción Celaya
JEJuan Erviti
Juan Erviti
LLLeire Leache
Leire Leache

9 September 2020 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LSLuis Carlos Saiz
Luis Carlos Saiz
JGJavier Gorricho
Javier Gorricho
JGJavier Garjón
Javier Garjón
MCMª Concepción Celaya
Mª Concepción Celaya
JEJuan Erviti
Juan Erviti
LLLeire Leache
Leire Leache

20 July 2018 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LSLuis Carlos Saiz
Luis Carlos Saiz
JGJavier Gorricho
Javier Gorricho
JGJavier Garjón
Javier Garjón
MCMª Concepción Celaya
Mª Concepción Celaya
JEJuan Erviti
Juan Erviti
LLLeire Leache
Leire Leache

29 April 2024 in Ageing Research Reviews
Verified
Journal Article
Closed access
VRVictoria Roncal-Belzunce
Victoria Roncal-Belzunce
MGMarta Gutiérrez-Valencia
Marta Gutiérrez-Valencia
LLLeire Leache
Leire Leache
LSLuis Carlos Saiz
Luis Carlos Saiz
JBJ Simon Bell
J Simon Bell
NMNicolas Martinez-Velilla
Nicolas Martinez-Velilla

15 December 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
LLLeire Leache
Leire Leache
MGMarta Gutiérrez-Valencia
Marta Gutiérrez-Valencia
LSLuis Carlos Saiz
Luis Carlos Saiz
JUJuan Uriz
Juan Uriz
FBFederico Bolado
Federico Bolado
JEJuan Erviti
Juan Erviti

30 December 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
JEJuan Erviti
Juan Erviti
JWJames Wright
James Wright
KBKen Bassett
Ken Bassett
Mohamed Ben-EltrikiMohamed Ben-Eltriki
Mohamed Ben-Eltriki
CJCiprian Jauca
Ciprian Jauca
TPThomas L Perry
Thomas L Perry
Objective The FOURIER trial showed a benefit of the PCSK9 inhibitor evolocumab over placebo with respect to cardiovascular outcomes in patients with cardiovascular disease. However, we observed some inconsistencies between the information in the Clinical Study Report (CSR) and that in the 2017 primary trial results publication. We aimed to restore the mortality data in the FOURIER trial based on the information contained in the death narratives in the CSR. Methods Mortality data in the primary results publication were compared with that in the CSR. In cases of discrepancy between the sources, an independent committee blindly readjudicated and restored the cause of death according to the information in the CSR narratives. Results For 360/870 deaths (41.4%), the cause of death adjudicated by the FOURIER clinical events committee differed from that declared by the local clinical investigator. When comparing the CSR information with the 2017 primary results publication, we found 11 more deaths from myocardial infarction in the evolocumab group (36 vs 25) and 3 less deaths in the placebo group (27 vs 30, respectively). In the CSR, the number of deaths due to cardiac failure in the evolocumab group was almost double those in the placebo group (31 vs 16). While cardiac and vascular deaths were not assessed as separate outcomes in the original trial analysis, after readjudication, we noted that cardiac deaths were numerically, but non-significantly, higher in the evolocumab group (113) than in the placebo group (88; relative risk (RR) 1.28, 95% CI 0.97 to 1.69, p=0.078), whereas non-cardiac vascular deaths were similar between groups (37 in each; RR 1.00, 95% CI 0.63 to 1.58, p=0.999). The reported HR for cardiovascular mortality in the original trial analysis was 1.05 (95% CI 0.88 to 1.25); after readjudication, we found a greater (although still non-significant) relative increase in cardiovascular mortality in the evolocumab treatment group (RR 1.20, 95% CI 0.95 to 1.51, p=0.13). Conclusion After readjudication, deaths of cardiac origin were numerically higher in the evolocumab group than in the placebo group in the FOURIER trial, suggesting possible cardiac harm. At the time the trial was terminated early, a non-significantly higher risk of cardiovascular mortality was observed with evolocumab, which was numerically greater in our readjudication. A complete restoration of the FOURIER trial data is required. In the meantime, clinicians should be sceptical about prescribing evolocumab for patients with established atherosclerotic cardiovascular disease. Trial registration numbers NCT01764633.